Shaunak Bele* 1
Naziya Tamboli 2
Shantanu Bele 3
Mayur Pawar 3
Vaibhav Khadul 3
Akshay Khatal 4
Hypertension: The World Health Organization (WHO) defines hypertension (excessive blood stress), as a circumstance wherein the stress with inside the blood vessels is 140/90 mmHg or above.
Table 1: Categories of hypertension.
|
Category |
Systole |
Diastole |
|
Optimal Normal |
<120 <130 |
<80 <85 |
|
Level1 (Mild-hypertension) |
140-159 |
90-99 |
|
Level2 (Moderate hypertension) |
160-179 |
100-109 |
|
Level3 (Severe hypertension) |
≥ 180 |
≥ 110 |
Endothelin-1plays a role in the pathophysiology of hypertension and controls blood pressure (BP) and vascular tone. It is a strong vasoconstrictor peptide that induces endothelial dysfunction, fibrosis, hypertensive damage to the end organs (including vascular hypertrophy and remodelling), neurohormonal and sympathetic stimulation and enhanced aldosterone production and secretion. Studies using human and animal models have demonstrated that hypertension increases the expression of vascular ET-1[1-3].
Figure 1: Aprocitentan’s chemical structure.
A potent oral-active dual ET receptor antagonist, Aprocitentan (As Figure 1) blocks the binding of ET-1 with a ratio of inhibitory potency of 1:16 of both ETA/ETB receptors [5]. A 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl) oxy] ethoxy} pyrimidin-4-yl replaces one of the amino groups of sulphonamides in this class member [6]. An orphan medication used to treat pulmonary arterial hypertension, Macitentan (derived by oxidative depropylation) has an active metabolite called Aprocitentan [7]. Aprocitentan lowers blood pressure in a dose-dependent manner & has been demonstrated to work in concert with RAS blockers. Therefore, when existing medications are insufficient to control high blood pressure, it may be a new treatment option. Our review's primary objectives were toprovide mechanism of action, contraindication, adverse effect, and drug interaction [4]. Resistant hypertension, as described through Judd and Calhoun (2014), is out of control blood stress regardless of triple therapy, that’s created from renin-angiotensin device blockers at suitable dosages, wonderful compliance with medicine administration, and the shortage of secondary hypertension.It is also commonly linked to an increase in intravascular volume and an excess of aldosterone. At every stage, the most often prescribed therapies for hypertension are based on RAS blockage and the resulting salt depletion. It would beanticipated that a new antihypertensive medication with an innovative mode of action would further reduce BP [8]. When it is provided in patients with uncontrolled hypertension in conjunction with current therapies and as a result, ought to show further clinical advantages [30]. Aprocitentan, a dual ETA/ETB antagonist, should be tested in conjunction with current treatments, especially RAS blockers, because it targets a distinct route. Use of the combination of RAS blockade plus a mineralocorticoid receptor antagonist (such as Spironolactone) is unlikely to be effective or safer compared to a combination of Aprocitentan with a RAS blocker. Since the occurrences of hyperkalemia and renal dysfunction are frequent unwanted side effects from pronounced pharmacologic inhibition of the renin-angiotensin-aldosterone axis, use of this regimen in conjunction with Aprocitentan could improve safety [9]. Endothelial cells predominately generate the 21-amino acid peptide known as endothelin-1. A number of triggers, such as a lack of oxygen shear stress, Angiotensin-II, hyperglycaemia and inflammatory cytokines, cause these endothelial cells to produce more of it [10–12]. It has exceptionally long-lasting effects and operates in a paracrine fashion, causing a potent vasoconstrictor effect [13–16]. Besides inducing endothelial dysfunction and cardiac and vascular remodelling, ET-1 is also involved in the kidney’s regulation of water and sodium ET-1 expression in the endothelium is upregulated in patients with severe hypertension and it is involved in the pathophysiology of vascular hypertrophy and blood pressure increase. Diabetic, obese, chronic renal disease and salt-sensitive hypertensive patients also have increased ET system activity [13-19]. According to experimental models, ET receptor antagonists can prevent as well as reversibly alter tissue changes in an organ-specific manner which may prove beneficial in the long run [21]. Additionally, it has been suggested that these benefits might not be related to the therapy's effect on hemodynamic [20-21].
Therefore, what is missing is the exact impact of the ET system on volume-dependent hypertension along with other end-organ dysfunctions, or coexisting intra related conditions of hypertension. Of particular note is the application of ET-1 receptor antagonists as a novel pharmacological approach to treat resistant hypertension [19-21]. Moreover, some data suggest that selective and mixed antagonists, regardless of ET receptor’s limitations, which stem from a poor cumulative side effect profile of sodium retention causing increased total body sodium, enhance forearm vasodilation and lower blood pressure in hypertensive patients [22, 23].
MECHANISM OF ACTION:
10.5281/zenodo.15263808